Personalis Inc. to Showcase Groundbreaking NeXT Personal® Assay at ASCO 2024

Personalis Inc., a prominent entity in the realm of advanced genomics for precision oncology, disclosed that it will feature two prominent podium presentations and several posters showcasing data for its NeXT Personal® whole genome-based, tumor-informed assay aimed at ultra-sensitive ctDNA detection. These presentations are scheduled for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place from May 31 to June 4, 2024, in Chicago, Illinois.

Dr. Richard Chen, Chief Medical Officer and Executive Vice President of R&D at Personalis, expressed pride in the selection of two Personalis studies for podium presentations at the ASCO 2024 Clinical Science Symposium. Highlighting the importance of these studies, he noted how the growing body of research underscores NeXT Personal's significant role in early detection of recurrent cancer through ultra-sensitive MRD testing.

The two studies chosen for podium presentations are:

1. Clinical Science Symposium: Emerging Role of ctDNA in Breast Cancer
- Presenter: Isaac Garcia-Murillas, PhD
- Overview: This study focuses on the ultra-sensitive tracking of ctDNA mutations to identify molecular residual disease and predict relapse in patients with early breast cancer.
- Abstract Number: 1010

2. Clinical Science Symposium: Hitting the Mark - The Ongoing Search for Immunotherapy Biomarkers
- Presenter: Rodrigo A Toledo, PhD, MBA
- Overview: This research examines the prognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors within the context of phase 1 clinical trials.
- Abstract Number: 2510

Further information about additional posters and abstracts from Personalis includes:

- Emerging Role of ctDNA in Breast Cancer
- Presenter: Andrew B. Nixon, PhD, MBA
- Overview: This abstract investigates the dynamics of ultra-sensitive ctDNA to monitor therapy response in gastroesophageal cancer patients treated with pembrolizumab.
- Abstract Number: 4025

- Breast Cancer—Local/Regional/Adjuvant
- Presenter: Adrienne Gropper Waks, MD
- Overview: This study highlights the prevalence and dynamics of circulating tumor DNA (ctDNA) in patients with HER2+ breast cancer undergoing neoadjuvant therapy with paclitaxel/trastuzumab/pertuzumab in the DAPHNe trial.
- Abstract Number: 588

- Gastrointestinal Cancer—Colorectal and Anal
- First Author: Joao Paulo Solar Vasconcelos, MD
- Overview: The focus here is on ctDNA kinetics in colorectal cancer patients treated with curative intent, using an ultrasensitive MRD assay in the VICTORI study.
- Abstract Number: e15625

Personalis Inc. is dedicated to revolutionizing cancer management through cutting-edge personalized testing. The company aims to establish a new paradigm for cancer care, providing guidance from initial biopsy through the patient's journey. Their highly sensitive assays integrate tumor and normal profiling with proprietary algorithms, delivering advanced insights as cancer evolves. Their products are designed to detect minimal residual disease (MRD) and recurrence at the earliest stages, aid in selecting targeted therapies through comprehensive genomic profiling, and enhance biomarker strategies for drug development. Personalis is headquartered in Fremont, California.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!